Saussele, Susanne
Hehlmann, Rüdiger
Fabarius, Alice
Jeromin, Sabine
Proetel, Ulrike
Rinaldetti, Sebastien
Kohlbrenner, Katharina
Einsele, Hermann
Falge, Christiane
Kanz, Lothar
Neubauer, Andreas
Kneba, Michael
Stegelmann, Frank
Pfreundschuh, Michael http://orcid.org/0000-0001-6982-8218
Waller, Cornelius F.
Oppliger Leibundgut, Elisabeth
Heim, Dominik
Krause, Stefan W.
Hofmann, Wolf-Karsten
Hasford, Joerg
Pfirrmann, Markus
Müller, Martin C.
Hochhaus, Andreas
Lauseker, Michael
Article History
Received: 8 November 2017
Revised: 8 January 2018
Accepted: 15 January 2018
First Online: 26 February 2018
Compliance with ethical standards
:
: The authors declare that they have no conflict of interest. S.S.: Novartis: Honoraria, Research Funding, Travel Other; B.-M.S.: Honoraria, Research Funding, Travel, Travel Other; Pfizer: Honoraria, Travel, Travel Other. R.H.: B.-M.S.: Research Funding; Novartis: Research Funding. S.J.: MLL Munich Leukemia Laboratory: Equity Ownership. A.N.: MedUpdate: Honoraria, Speakers Bureau. M.K.: Novartis: Consultancy, Equity Ownership, Honoraria, Membership on an entity’s Board of Directors or advisory committees, Research Funding. M.Pfi.: Novartis: Consultancy; B.-M.S.: Honoraria. A.H.: Novartis: Consultancy, Honoraria, Research Funding; B.-M.S.: Consultancy, Honoraria; ARIAD: Honoraria, Research Funding; Pfizer: Consultancy, Research Funding. M.C.M.: Novartis: Honoraria, Research Funding; B.-M.S.: Honoraria, Research Funding; ARIAD: Honoraria, Research Funding; Pfizer: Honoraria, Research Funding.